Global Allergy Immunotherapies Market - Industry Analysis and Forecast | Technavio

Technavio has published a new market research report on the global allergy immunotherapies market from 2018-2022. (Graphic: Business Wire)

LONDON--()--Market research firm Technavio has announced the release of their latest report on the global allergy immunotherapies market. This new report will provide expert market insights for the forecast period 2018-2022.

The report will follow up on Technavio’s previous allergy immunotherapies research, offering an up-to-date analysis of the market concerning the current market scenario, latest trends and drivers, and the overall global environment. The report will also provide new predictions for the forecast period based on an in-depth analysis of the market.

The upgraded research report on the global allergy immunotherapies market is an integral part of Technavio’s infectious and rare diseases portfolio. Technavio covers an extensive range of market research reports on the infectious and rare diseases market, covering different regions and top industry segments. Some of the topics include conjunctivitis, gaucher disease, animal wound care, and veterinary clostridium vaccine.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers

Global market growth opportunities

Technavio’s previous report on the global allergy immunotherapies market projected that in terms of geography, Europe dominated the global immunotherapies market. During 2015, around 90 million individuals were reported with respiratory allergies in Europe.

In the previous report, a senior research analyst at Technavio stated, “Although the existing therapies are highly effective in relieving and controlling allergy symptoms, the market still requires drugs that not only reduce inflammation but also prevent irreversible airway remodeling. Globally, only 55% of all allergic rhinitis cases have been diagnosed. Additionally, allergic rhinitis and asthma are chronic diseases that cannot be cured completely, so most patients need lifelong treatment and lifestyle adjustments.”

Technavio’s new report on the global allergy immunotherapies market will evaluate the key geographical regions and their behavior over the past four years, introducing new data and observations and providing new predictions.

Looking for the latest information on the global allergy immunotherapies market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Detailed analysis at your fingertips

Some of the topics that will be revisited in the new report include:

  • Market size and growth rate through 2022
  • Top factors driving the market growth
  • Competitive landscape and market share analysis of the key players
  • Market opportunities and factors impeding growth

Technavio’s report on the global allergy immunotherapies market for the period 2018-2022 is available to order now and will be delivered within one week of purchase.

 

Save big with Technavio this May!

Find out what companies are venturing in to beat the heat this summer! Technavio indulges you with a massive 20% OFF on all non-alcoholic beverages reports for the entire month.

OR

Technavio honors the achievements and efforts of Motherhood this Mother's Day by offering a whopping 30% OFF on all cosmetics and toiletry reports. Offer valid from 7th May for a limited period.

 

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Market research firm Technavio has announced the release of their latest report on the global allergy immunotherapies market for 2018-2022.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com